Λόγος Ελίσσομαι άγνοια medisch mondneusmasker type 2 Belgium Στο ΕΔΑΦΟΣ Δολοφονώ Αμπέρ
World AIDS Day: Peter Piot collection - Library, Archive & Open Research Services blog
Siemens Healthineers | Corporate Home
Vaccines | Free Full-Text | Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in Belgium
Behavioral Sciences | Free Full-Text | Anxiety and Depression in Belgium during the First 15 Months of the COVID-19 Pandemic: A Longitudinal Study
Dutch medical specialists: focus on healthy pensions | Interviews | IPE
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial | Nature Medicine
Viruses | Free Full-Text | Nationwide Harmonization Effort for Semi-Quantitative Reporting of SARS-CoV-2 PCR Test Results in Belgium
Frontiers | The 2000HIV study: Design, multi-omics methods and participant characteristics
Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020 - The Lancet
Mondneusmaskers of -kapjes: verschillende soorten | Mondmaskers | Inspectie Gezondheidszorg en Jeugd
Mobile Workspace with Adjustable Shelves, Locking Casters, TAA | Eaton
Mondneusmaskers of -kapjes: verschillende soorten | Mondmaskers | Inspectie Gezondheidszorg en Jeugd
JCM | Free Full-Text | Gender Difference in the Effects of COVID-19 Pandemic on Mechanical Reperfusion and 30-Day Mortality for STEMI: Results of the ISACS-STEMI COVID-19 Registry
Type 2, niet-medisch of FFP2: zo verschillen de soorten mondkapjes van elkaar - EenVandaag
Frontiers | Case report: the effects of cerebellar tDCS in bilingual post-stroke aphasia
JCM | Free Full-Text | The COVID-19 Pandemic and Dental Professionals’ Infection Risk Perception: An International Survey
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial - The Lancet
Endovascular treatment versus no endovascular treatment after 6–24 h in patients with ischaemic stroke and collateral flow on CT angiography (MR CLEAN-LATE) in the Netherlands: a multicentre, open-label, blinded-endpoint, randomised, controlled, phase